Compare FLNG & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNG | MLTX |
|---|---|---|
| Founded | 2006 | 2021 |
| Country | Bermuda | Switzerland |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2019 | 2020 |
| Metric | FLNG | MLTX |
|---|---|---|
| Price | $31.32 | $15.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $23.00 | ★ $27.50 |
| AVG Volume (30 Days) | 322.4K | ★ 1.3M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 9.40% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.14 | N/A |
| P/E Ratio | $19.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.00 | $5.95 |
| 52 Week High | $33.40 | $62.75 |
| Indicator | FLNG | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.57 | 36.32 |
| Support Level | $28.72 | $14.84 |
| Resistance Level | $33.22 | $19.24 |
| Average True Range (ATR) | 0.90 | 0.73 |
| MACD | 0.04 | -0.07 |
| Stochastic Oscillator | 61.02 | 13.78 |
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The company's fleet consists of several LNG carriers on the water, and all of its vessels are of the latest generation equipped with two-stroke propulsion. Its fleet consists of M-type, Electronically Controlled, Gas Injection (MEGI) LNG carriers and Generation X Dual Fuel (X-DF) LNG carriers, offering improvements in fuel efficiency and thus also carbon footprint compared to the older steam and four-stroke propelled ships. The company has one reportable segment: vessel operations, which generates revenue from the chartering of vessels to customers.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.